麻豆传媒

Diabetes accounted for in the U.S. over each of the past 2 years. (Reuters)

People whose -- i.e., bright during the day and dim in the evening -- tended to have lower blood glucose levels. "These findings suggest that the indoor light environment of insulin-resistant individuals can modulate metabolic parameters in a time-of-day-dependent manner to influence metabolic health in the long-term," the researchers wrote in Diabetologia.

According to a lawsuit filed in federal court, for allegedly stealing trade secrets related to new diabetes and obesity developments. (Reuters)

-- removal of both ovaries -- was linked to an 18% higher rate of dementia, while unilateral oophorectomy was not. "Given the robust body of evidence suggesting potential long-term adverse effects associated with oophorectomy before the average age of menopause, risk-reducing oophorectomy should be limited to those women with an inherited high risk for cancer," said Stephanie Faubion, MD, MBA, medical director of the North American Menopause Society, in a statement. (Menopause)

Teenage boys with severe obesity saw a significant after undergoing bariatric surgery. Total testosterone increased from 6.7 nmol/L at baseline to 17.6 nmol/L 2 years after surgery. (European Journal of Endocrinology)

said it is still working on fixing the supply chain kink with Wegovy (semaglutide 2.4 mg) production, which cropped up at the end of 2021. (FiercePharma)

Adults who lost weight -- at least 1.1 lb or more per 5 years -- saw a significant . "Based on our findings, we would not recommend weight loss for all adults. But the results suggest that overweight and obese adults may benefit from weight loss," said study author Kathryn Hughes Barry, PhD, MPH, of the University of Maryland School of Medicine, in a statement. (JNCI Cancer Spectrum)

Obesity was also tied to a higher risk of developing a , like uterine fibroids, heavy menstrual bleeding, PCOS, and preeclampsia, just to name a few. (PLOS Medicine)

Viridian Therapeutics announced that the FDA cleared its investigational new drug application for VRDN-002, a next-generation IGF-1R antibody for the to initiate a first-in-human phase I clinical trial.

Comment